Multaq - Investigational Agent for the Treatment of Cardiac Arrhythmia, No Country

Print

Dronedarone is a new Class III antiarrhythmic drug under development by Sanofi-Aventis.
 
Next»

Return to Profile




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development